Nicotine dependence and smoking cessation

Journal of Central South University (Medical Sciences)

Volumn 34, Issue 11, 2009, Pages 1049-1057

  Tan, Linxiang ^a   Tang, Quansheng ^a   Hao, Wei ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Brief intervention; Nicotine dependence; Pharmacotherapy; Smoking cessation

Indexed keywords

AMFEBUTAMONE; BENZAZEPINE DERIVATIVE; DOPAMINE UPTAKE INHIBITOR; NICOTINIC AGENT; QUINOXALINE DERIVATIVE; VARENICLINE;

HUMAN; METHODOLOGY; PSYCHOLOGICAL ASPECT; REVIEW; SMOKING CESSATION; TOBACCO DEPENDENCE;

BENZAZEPINES; BUPROPION; DOPAMINE UPTAKE INHIBITORS; HUMANS; NICOTINIC AGONISTS; QUINOXALINES; SMOKING CESSATION; TOBACCO USE DISORDER;

EID: 73349097880     PISSN: 16727347     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (35)

1. YANG Gonghuan, MA Jiemin, LIU Na, et al. Smoking and passive smoking in China, 2002 [J]. Chinese Journal Epidemiology, 2005,26(2):77-83.
2. Hao W, Young D S, Li L J, et al. Psychoactive substance use in three sites in China: gender differences and related factors [J]. Addiction, 1995, 90 (11): 1505-1517.
3. Mackay J, Eriksen M, Shafey O. The tobacco atlas [M]. 2 nd ed. Atlanta, Georgia: American Cancer Society Myriad Editions Limited, 2006. Also available online at; http://www.myriadeditions.com/statmap/.
4. US Department of Health and Human Services. The health consequences of smoking. A report of the surgeon general [M]. Atlanta: Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, 2004.
5. Roman G C. Vascular dementia prevention: a risk factor analysis [J]. Cerebrovasc Dis, 2005, 20 (Suppl 2): 91-100.
6. Willigendael E M, Teijink J A, Bartelink M L, et al. Influence of smoking on incidence and prevalence of peripheral arterial disease [J]. J Vasc Surg, 2004, 40(6): 1158-1165.
7. World Health Organization. An international treaty for tobacco control [EB/OL]. (2003-08-12) [2009-05-20] http://www.who.int/features/2003/08/en
8. Mackay J, Eriksen M. The tobacco atlas [M]. Geneva, Switzerland: World Health Organization, 2002.
9. Jarvis M J. Why people smoke [J]. BMJ, 2004, 328 (7434): 211-219.
10. HAO Wei. Tobacco dependence is a chronic additive disease [J]. Chinese Journal Internal Medicine, 2008, 47 (6): 523-525.
11. Centers for Disease Control and Prevention. The health consequences of smoking: nicotine addiction A report of the surgeon General [M]. Washington DC: US Department of Health and Human Services, 1988.
12. Picciotto M R, Zoli M, Changeux J. Use of knock - out mice to determine the molecular basis for the actions of nicotine [J]. Nicotine Tob Res, 1999 (Suppl 2): S121-S125.
13. Benowitz N L. Pharmacodynamic aspects of cigarette smoking and nicotine addiction [J]. N Engl J Med, 1988, 319 (13): B18-B30.
14. American Psychiatric Association. Diagnostic and statistical manual of mental disorders [M/OL]. IV-TR. Washington, DC: American Psychiatric Association, 2000 [2006-11-07]. http://psychiatryonline.com.
15. West R, Shiffman S. Fast facts: smoking cessation [M]. Oxford, United Kingdom: Health Press Limited, 2004.
16. Richard H. The health consequences of smoking on the human body [R/OL]. CDC: Surgeon General, 2004 [2009-06-20]. http://www.cdc.gov/tobacco/sgr/sgr- 2004/sgranimation/flash/index.html.
17. American Cancer Society. Guide to quitting smoking [EB/OL]. [2009-07-25]. http://www.cancer.org/docro-ot/PED/content/PED-10-13X-Guide-for-Quitting- Smoking.asp.
18. Fiore M C, Bailey W C, Cohen S J, et al. Clinical practice guideline: treating tobacco use and dependence [M/OL]. U.S. Department of Health and Human Services, Public Health Service, 2000 [2009-07-16]. http://www.surgeongeneral. gov/tobacco/treating-tobacco-use.pdf.
19. American Heart Association. Nicotine substitutes / nicotine replacement therapy [EB/OL]. [2009-06-10]. http://www.americanheart.org/presenter.jhtml? identifier=4615.
20. Silagy C, Lancaster T, Stead L, et al. Nicotine replacement therapy for smoking cessation [J]. Cochrane Database Syst Rev, 2004, (3): CD000146.
21. Stead L, Lancaster T. Nicotine replacement therapy for smoking cessation: Cochrane systematic review [J]. Int J Epidemiol, 2005, 34 (5): 1001-1003.
22. Henningfield J E, Fant R V, Buchhalter A R, et al. Pharmacotherapy for nicotine dependence [J]. CA Cancer J Clin, 2005, 55(5): 281-299.
23. Ockene J K, Kristeller J L, Donnelly G. Tobacco [M] // Galanter M, Kleber H D. Textbook of substance abuse treatment. 2 nd ed. Washington: American Psychiatric Press, 2005.
24. Sweeney C T, Fant R V, Fagerström K O, et al. Combination nicotine replacement therapy for smoking cessation: rationale, efficacy and tolerability [J]. CNS Drugs, 2001, 15 (6): 453-467.
25. Hughes J R, Stead L F, Lancaster T. Antidepressants for smoking cessation [J]. Cochrane Database Syst Rev,2004, 24(1): CD000031.
26. Glaxo-SmithKline. ZYBAN® (bupropion hydrochloride) Sustained-Release Tablets [EB/OL]. [2009-08-04]. http://us.gsk.com/products/assets/us-zyban.pdf.
27. Jorenby D E, Leischow S J, Nides M A, et al. A controlled trial of sustained - release bupropion SR, a nicotine patch, or both for smoking cessation [J]. N Engl J Med, 1999, 340 (9):685-691.
28. Rollema H, Coe J W, Chambers L K, et al. Rationale, pharmacology and clinical efficacy of partial agonists ofα4 β 2 nACh receptors for smoking cessation [J]. Trends Pharmacol Sci, 2007, 28(7): 316-325.
29. Pfizer. Champix Summary of product characteristics [M]. Sandwich, UK: Pfizer Ltd, 2006.
30. Cahill K, Stead L F, Lancaster T. Nicotine receptor partial agonists for smoking cessation [J]. Cochrane Database Syst Rev, 2007, 24(1): CD006103.
31. Hays J T, Ebbert J O, Sood A. Efficacy and safety of vareni-cline for smoking cessation [J]. Am J Med, 2008, 121 (4 Suppl 1): S32-S42.
32. Gonzales D, Rennard S I, Nides M, et al. Varenicline Phase 3 Study Group. Varenicline, anα4 β2 nicotinic acetylcholine receptor partial agonist, vs sustained - release bupropion and placebo for smoking cessation: a randomized controlled trial [J]. JAMA, 2006, 296(1): 47-55.
33. Jorenby D E, Hays J T, Rigotti N A, et al. Varenicline Phase 3 Study Group. Efficacy of varenicline, anα 4 β 2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial [J]. JAMA,2006,296 (1): 56-63.
34. West R, Hajek P, Stead L, et al. Outcome criteria in smoking cessation trials: proposal for a common standard [J]. Addiction, 2005, 100(3): 299-303.
35. Ezzati M, Lopez A D. Regional disease specific patterns of smoking-attributable mortality in 2000 [J]. Tobacco Control, 2004, 13 (4): 388-395.